Laboratorios Farmaceuticos Rovi SA 2022 IR
The report highlights Laboratorios Farmaceuticos ROVI's strong financial and ESG performance in 2022, achieving a 26% increase in operating revenue to 817.7 million euros and a 30% increase in net profit to 199.7 million euros. Strategically, the company launched Okedi in Europe, extended its collaboration with Moderna for ten years, and established the Glicopepton Biotech joint venture for heparin self-supply. In ESG, ROVI achieved the top ranking in the pharmaceutical industry by Sustainalytics with an improved score of 17.3. Environmentally, the company maintained Scope 1 and 2 carbon neutrality for the third consecutive year and expanded its emissions measurement to Scope 3.
Company: Laboratorios Farmaceuticos Rovi SA
Sector: Manufacturing
Country: Spain
Year: 2022
Type: IR
Pages: 205
Back to company
Laboratorios Farmaceuticos Rovi SA
Integrated Report
The report highlights Laboratorios Farmaceuticos ROVI's strong financial and ESG performance in 2022, achieving a 26% increase in operating revenue to 817.7 million euros and a 30% increase in net profit to 199.7 million euros. Strategically, the company launched Okedi in Europe, extended its collaboration with Moderna for ten years, and established the Glicopepton Biotech joint venture for heparin self-supply. In ESG, ROVI achieved the top ranking in the pharmaceutical industry by Sustainalytics with an improved score of 17.3. Environmentally, the company maintained Scope 1 and 2 carbon neutrality for the third consecutive year and expanded its emissions measurement to Scope 3.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees